The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) is a huge mover today! About 109,885 shares traded hands. Global Blood Therapeutics Inc (NASDAQ:GBT) has risen 13.61% since March 11, 2016 and is uptrending. It has outperformed by 8.15% the S&P500.
The move comes after 7 months negative chart setup for the $659.32 million company. It was reported on Oct, 14 by Barchart.com. We have $16.07 PT which if reached, will make NASDAQ:GBT worth $39.56 million less.
Analysts await Global Blood Therapeutics Inc (NASDAQ:GBT) to report earnings on November, 10. They expect $-0.59 EPS, up 34.44% or $0.31 from last year’s $-0.9 per share. After $-0.58 actual EPS reported by Global Blood Therapeutics Inc for the previous quarter, Wall Street now forecasts 1.72% negative EPS growth.
Global Blood Therapeutics Inc (NASDAQ:GBT) Ratings Coverage
Out of 4 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Global Blood Therapeutics has been the topic of 6 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Tuesday, September 8 by Goldman Sachs. The firm earned “Buy” rating on Friday, June 17 by Empire. On Tuesday, September 8 the stock rating was initiated by Wedbush with “Outperform”. The stock has “Outperform” rating given by Cowen & Co on Tuesday, September 8. Morgan Stanley initiated Global Blood Therapeutics Inc (NASDAQ:GBT) on Tuesday, September 8 with “Overweight” rating.
According to Zacks Investment Research, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.”
More notable recent Global Blood Therapeutics Inc (NASDAQ:GBT) news were published by: Globenewswire.com which released: “Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief …” on October 12, 2016, also Reuters.com with their article: “BRIEF-Global Blood Therapeutics files for mixed shelf offering of up to $2…” published on October 14, 2016, Fool.com published: “Why Global Blood Therapeutics Inc Shares Are Tanking Today” on December 07, 2015. More interesting news about Global Blood Therapeutics Inc (NASDAQ:GBT) were released by: Marketwatch.com and their article: “Global Blood Therapeutics shares jump after positive results for pivotal drug” published on June 10, 2016 as well as Globenewswire.com‘s news article titled: “Global Blood Therapeutics Announces Participation at Two Upcoming Investor …” with publication date: August 31, 2016.
GBT Company Profile
Global Blood Therapeutics, Inc., incorporated on February 04, 2011, is a clinical-stage biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. The Firm is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Firm is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). HAE is a rare, genetic disorder characterized by severe and potentially life-threatening systemic inflammation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.